STOCK TITAN

Tandem Diabetes Care (TNDM) Stock News, Oct-Dec 2020

TNDM Nasdaq

Tandem Diabetes Care reports developments in automated insulin delivery and diabetes technology. The company manufactures and sells pump systems including Tandem Mobi and the t:slim X2 insulin pump, both powered by Control-IQ+ advanced hybrid closed-loop technology. News commonly covers FDA clearances, pump and mobile-app compatibility, continuous glucose monitoring integrations, and product portfolio updates for people with diabetes.

Company updates also address quarterly and annual operating results, worldwide and U.S. sales trends, pump shipments, gross margin, financial guidance, reimbursement-model changes, investor conference presentations, and capital actions such as convertible debt financing.

Rhea-AI Summary

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced the appointment of Rajwant (Raj) Singh Sodhi as an independent board member effective January 1, 2021. He succeeds Edward Cahill, who has served since May 2009. Raj, president of the SaaS business at ResMed, brings over 25 years of digital strategy experience across healthcare, financial services, and telecom. Tandem's CEO, John Sheridan, highlighted Raj's expertise in software technologies as valuable for the company's growth and innovation in diabetes care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
management
-
Rhea-AI Summary

Tandem Diabetes Care (TNDM) reported strong Q3 2020 results with a 31% increase in sales to $123.6 million, up from $94.7 million in Q3 2019. Worldwide pump shipments rose 23% to 22,021 units. Domestic sales surged 36% to $107.5 million, while international sales saw a modest 2% increase. Although operating margin improved to negative 1%, a net loss of $9.4 million was recorded, higher than the previous year’s $2.9 million loss. The company updated its 2020 sales guidance to $465-$475 million, expecting 28%-31% annual growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
-
Rhea-AI Summary

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced upcoming presentations at three significant virtual investor conferences. The first will take place at the 29th Annual Credit Suisse Healthcare Conference on November 9, 2020, at 2:00 p.m. ET. The second event is the Stifel 2020 Healthcare Conference on November 17, 2020, at 4:40 p.m. ET. Lastly, the Nasdaq 43rd Investor Conference will occur on December 4, 2020, at 12:30 p.m. ET. Webcasts of these presentations will be available live and archived for 30 days on the company’s Investor Center website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
conferences
Rhea-AI Summary

Tandem Diabetes Care (NASDAQ: TNDM) will announce its third quarter 2020 results on November 5, 2020, after market close. A conference call and webcast will be held at 4:30 PM ET to discuss the financial and operational results. This session can be accessed through a toll-free number or via a webcast link. An archive of the event will be available for 30 days on the company’s Investor Center website. Tandem is known for its innovative insulin delivery systems, notably the t:slim X2 insulin pump.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags

FAQ

What is the current stock price of Tandem Diabetes Care (TNDM)?

Tandem Diabetes Care (TNDM) last closed at $16.65.

What is the market cap of Tandem Diabetes Care (TNDM)?

The market cap of Tandem Diabetes Care (TNDM) is approximately $1.2B.